Kevin R. Sayer Sells 33,359 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

DexCom Stock Performance

NASDAQ DXCM opened at $86.83 on Friday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The business’s 50-day moving average price is $80.49 and its 200 day moving average price is $76.67. The firm has a market cap of $33.92 billion, a P/E ratio of 51.99, a P/E/G ratio of 2.22 and a beta of 1.12.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Wells Fargo & Company increased their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Oppenheimer cut their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. upped their price target on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $99.29.

Hedge Funds Weigh In On DexCom

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Blue Whale Capital LLP grew its holdings in shares of DexCom by 91.9% during the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after buying an additional 113,000 shares during the last quarter. Taylor Frigon Capital Management LLC lifted its position in DexCom by 51.6% in the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after purchasing an additional 11,075 shares during the period. Brooktree Capital Management acquired a new stake in DexCom in the third quarter valued at about $683,000. National Pension Service lifted its position in DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after purchasing an additional 37,363 shares during the period. Finally, Intact Investment Management Inc. acquired a new stake in DexCom in the third quarter valued at about $650,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.